What Doctor's Are Saying

"Recent studies have demonstrated that MSCs can be persuaded to generate completely unrelated cell types such as brain cells, liver cells, and lung cells. These findings, combined with the relative ease of MSC isolation. . . suggest that these stem cells may be ideal for the treatment of a wide range of diseases, including disorders of the nervous system." Dale Woodbury, UMDNJ-Robert Wood Johnson Medical School and member of the Ira B. Black Center for Stem Cell Research.

"Mesenchymal stem cells (MSCs)derived from Wharton's jelly are a primitive cell population likely trapped in the connective tissue matrix cushioning the umbilical blood vessels early during fetal ontogeny. As such, they resemble fetal mesenchymal stem cells (derived from fetal tissues as early as 8 weeks' gestation) rather than adult mesenchymal stem cells based upon population doubling times and more extensive expansion prior to senescence. These Wharton's jelly cells (W. J. CS) are of great therapeutic potential because large number of cells are easily isolated and may be better tolerated following transplantation because of their low immunogenicity and immune suppression. The cells are a potential powerful device for tissue engineering, cell and gene therapy for a variety of genetic or inherited diseases, as well as for acquired diseases since W.JCs can be induced to form adipose tissue, bone, cartilage, skeletal muscle, cardio myocyte-like cells and neural cells and could be used to treat protein deficiencies, disorders of bone and cartilage and the heart,bone marrow stromal disorders as well as neurological diseases such as Parkinson's disease ,multiple sclerosis, cerebrovascular accidents (stroke) as well as perinatal hypoxia/asphyxia and even cerebral palsy." - Curtis L. Cetrulo, M.D. Professor Tufts University School of Medicine. President, International Cord Blood Society.